Search Results

You are looking at 1 - 10 of 181 items for :

  • "risk stratification" x
Clear All
Full access

George Rodrigues, Himu Lukka, Padraig Warde, Michael Brundage, Luis Souhami, Juanita Crook, Fabio Cury, Charles Catton, Gary Mok, Andre-Guy Martin, Eric Vigneault, Jim Morris, Andrew Warner, Sandra Gonzalez Maldonado, Tom Pickles and the Genitourinary Radiation Oncologists of Canada (GUROC)

The management of nonmetastatic prostate cancer is complex because of the interplay of multiple considerations, including risk stratification, relative treatment efficacy/toxicity, competing risk of death from cancer versus other causes, and

Full access

Jeffrey A. Kline and David W. Miller

an ICU setting. Conversely, 103 of 1880 (5.4%) patients were transferred from the ICU to a ward bed within 24 hours. 3 Initial risk stratification of patients with an acute PE might identify a more appropriate admission location in a small percentage

Full access

Hugo J.A. Adams, John M.H. de Klerk, Rob Fijnheer, Stefan V. Dubois, Rutger A.J. Nievelstein and Thomas C. Kwee

Prognostic Index (IPI) has been the most widely used risk stratification index for aggressive NHL since it was published in 1993. 3 Recently, however, a new NCCN International Prognostic Index (NCCN-IPI) was developed, which is exclusively applicable to

Full access

James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D’Amico, Brian J. Davis, Tanya Dorff, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Michael Hurwitz, Joseph E. Ippolito, Christopher J. Kane, Michael R. Kuettel, Joshua M. Lang, Jesse McKenney, George Netto, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, Thomas J. Pugh, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ahmad Shabsigh, Eric J. Small, Daniel E. Spratt, Sandy Srinivas, Jonathan Tward, Dorothy A. Shead and Deborah A. Freedman-Cass

cancer and life expectancy ≥10 years (see “Tumor Multigene Molecular Testing,” page 488). The Decipher molecular assay can be considered as part of counseling for risk stratification in patients with PSA resistance/recurrence after radical prostatectomy

Full access

Erin R. Weeda, Jonathan T. Caranfa, Simon B. Zeichner, Craig I. Coleman, Elaine Nguyen and Christine G. Kohn

Numerous risk stratification tools exist to predict early complications in patients with acute venous thromboembolism (VTE). 1 – 6 Evidence suggests that these tools can potentially aid both physicians in making difficult patient disposition

Full access

John Fanikos and Samuel Z. Goldhaber

International Cooperative Pulmonary Embolism Registry (ICOPER) . Lancet 1999 ; 353 : 1386 – 1389 . 21. Goldhaber SZ Elliott CG . Acute pulmonary embolism: part II: risk stratification, treatment, and prevention . Circulation 2003 ; 108 : 2834

Full access

Margaret R. O’Donnell

Two major prognostic factors for outcomes with acute myeloid leukemia (AML) therapy center on cytogenetic/molecular markers and patient age. With the paucity of novel agents available for the treatment of AML, clinicians are forced to fine-tune existing treatment strategies based on risk status to achieve the best results. Dr. Margaret R. O’Donnell of the City of Hope Cancer Center explored the prognostic implications of molecular mutations and other risk factors in the treatment of AML and presented an update of the current treatment strategies, sharing relevant clinical trial data on which recommendations are based. She also provided a glimpse of a novel non-chemotherapy approach to acute promyelocytic leukemia, which has had a major impact on treatment guidelines for this hematologic malignancy.

Full access

Robert E. Glasgow, David H. Ilson, James A. Hayman, Hans Gerdes, Mary F. Mulcahy and Jaffer A. Ajani

adenocarcinoma in Barrett's esophagus. After successful EMR treatment, patients should undergo surveillance endoscopy with biopsy every 3 months for 1 year, and then annually. Table 1 Risk Stratification for Endoscopic Therapy in Early Esophageal Cancer

Full access

Alok A. Khorana

largest, Prophylaxis of Thromboembolism during Chemotherapy (PROTECHT) trial and SAVE-ONCO included patients with a mix of solid tumors, 10 , 11 as did the Microtec study, which also included biomarker-based risk stratification. 12 Two other RCTs, FRAGEM

Full access

Ashraf Badros

, bortezomib, and lenalidomide may neutralize the effects of negative prognostic factors. An effective means of risk stratification is required so that patients with poor risk may be offered more aggressive treatment or be entered into clinical trials of novel